BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nkuize M, Sersté T, Buset M, Mulkay JP. Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. Ther Clin Risk Manag 2016;12:861-72. [PMID: 27350749 DOI: 10.2147/TCRM.S77788] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS Jr; RESCUE and ACTG A5348 study investigators. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver Int 2018;38:1010-21. [PMID: 29091342 DOI: 10.1111/liv.13616] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
2 Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S, Kato M, Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H, Shibatoge M, Takaguchi K, Hattori T, Sata M, Koike K. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. Exp Ther Med 2019;18:596-604. [PMID: 31258695 DOI: 10.3892/etm.2019.7616] [Reference Citation Analysis]
3 Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K, Mozer-Lisewska I, Kozielewicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci 2017;62:387-92. [PMID: 28554119 DOI: 10.1016/j.advms.2017.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
4 Sulkowski M, Ionescu-Ittu R, Macaulay D, Sanchez-Gonzalez Y. The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data. Adv Ther 2020;37:4709-19. [PMID: 32929647 DOI: 10.1007/s12325-020-01492-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Krol E, Pastuch-Gawolek G, Chaubey B, Brzuska G, Erfurt K, Szewczyk B. Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds. Molecules 2018;23:E1435. [PMID: 29899276 DOI: 10.3390/molecules23061435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Bendas ER, Rezk MR, Badr KA. Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers. Clin Drug Investig 2018;38:439-48. [PMID: 29417463 DOI: 10.1007/s40261-018-0622-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]